[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fj_UfXx22cCnvYuX5gTQ1zIcjeeMHBBVwwdDWaUKT4dU":8,"$fiwOb9qw8VAGSREE7xtJDDfn3Lug_3ChGxHdtsQq1mNA":55,"$fOM719str-J1QA6sABCeqHl5Z_vh90l8FyYyGnGHbVEs":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},46026,867332,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//NaWaskW0OJ0kWUt2Jjayxy1WaVEph7oE.png","宋阳","新乡医学院第一附属医院","普外科","住院医师",71,0,"HER-2过表达型乳腺癌用药全攻略——安全规范用药的7个关键细节","","https://ystcdn.venuertc.com/venue/AI/3d1cb82e-7446-40f0-88fc-5b39f23e5c12.jpg","\u003Cdiv class=\"bcg-guide-main\">\n  \u003Ch2 id=\"material_title\" class=\"bcg-guide-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">HER-2过表达型乳腺癌用药全攻略——安全规范用药的7个关键细节\u003C/h2>\n  \n  \u003Cdiv class=\"bcg-guide-section bcg-guide-bg1\">\n    \u003Ch2 class=\"bcg-guide-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 ⭐ 基本药物类型及主要用途\u003C/h2>\n    \u003Cp class=\"bcg-guide-p\">\n      在乳腺肿瘤治疗中，HER-2靶向药物（如曲妥珠单抗、帕妥珠单抗）、常规化疗药物（如紫杉醇类）、以及相关辅助药物被广泛应用。这些药物以针对HER-2蛋白过度表达为特点，主要用于联合方案中，配合手术达到治疗目标。下文将为你详细介绍7个安全用药要点，让正确用药成为健康的第一步。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"bcg-guide-section bcg-guide-bg2\">\n    \u003Ch2 class=\"bcg-guide-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 💉 靶向药物的作用机制\u003C/h2>\n    \u003Cp class=\"bcg-guide-p\">\n      曲妥珠单抗（Trastuzumab）和帕妥珠单抗（Pertuzumab）是针对HER-2蛋白的靶向抗体。它们通过结合肿瘤细胞表面的HER-2受体，阻止信号传递路径，从而抑制肿瘤细胞增殖。紫杉醇类药物则通过干扰微管蛋白聚合，影响细胞分裂。（参考：Swain, S.M., et al. \"Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Breast Cancer\", New England Journal of Medicine, 2015）\n    \u003C/p>\n    \u003Cdiv class=\"bcg-guide-tip bcg-guide-tip1\">\n      ✅ \u003Cspan>正确做法：\u003C/span> 任何靶向治疗都应在医生指导下使用，绝不自行调整剂量和用药周期。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"bcg-guide-section bcg-guide-bg3\">\n    \u003Ch2 class=\"bcg-guide-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 ⏰ 用法用量及给药路径\u003C/h2>\n    \u003Cp class=\"bcg-guide-p\">\n      HER-2靶向药物和紫杉醇类多为静脉输注给药。曲妥珠单抗首次剂量通常按体重（8 mg/kg）静脉注射，之后每次维持剂量（6 mg/kg）每三周一次。帕妥珠单抗也是静脉给药，首剂840 mg，以后为420 mg，每三周一次。紫杉醇类按方案给药，常见为每周一次，剂量由医生根据体表面积计算。\n    \u003C/p>\n    \u003Cdiv class=\"bcg-guide-tip bcg-guide-tip2\">\n      👩‍⚕️ \u003Cspan>正确做法：\u003C/span> 每次用药需专业医护团队操作，严禁自行注射。每次输液需全程观察，并按约定时间规律就诊。\n    \u003C/div>\n    \u003Cp class=\"bcg-guide-sub\">\n      使用案例：有位55岁女性患者，在新辅助治疗期间严格遵循三周一次的曲妥珠单抗和帕妥珠单抗输注，配合紫杉醇方案，获得良好耐受性和效果。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"bcg-guide-section bcg-guide-bg4\">\n    \u003Ch2 class=\"bcg-guide-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 💊 剂型及特殊服药技巧\u003C/h2>\n    \u003Cp class=\"bcg-guide-p\">\n      当前主流的HER-2靶向药物多为注射剂型（液体溶液）。紫杉醇类亦为注射剂。由于注射用药的特殊性，需避免药液接触皮肤或黏膜，严防外渗。部分人群可使用皮下针剂，但均需由专业人员完成。\n    \u003C/p>\n    \u003Cdiv class=\"bcg-guide-tip bcg-guide-tip3\">\n      🟣 \u003Cspan>正确做法：\u003C/span> 发现注射部位有红肿、疼痛或硬结应立即告知医务人员，以防药液外渗导致局部损伤。\n    \u003C/div>\n    \u003Cp class=\"bcg-guide-sub\">\n      \u003Cspan>需注意：\u003C/span> 绝不能口服或自行调整注射频率，药品剂型决定了其用药安全性。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"bcg-guide-section bcg-guide-bg5\">\n    \u003Ch2 class=\"bcg-guide-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 ⚡ 药物相互作用与用药间隔\u003C/h2>\n    \u003Cp class=\"bcg-guide-p\">\n      靶向药物与化疗药物联合使用效果更佳，但部分药物合用时存在相互影响。比如曲妥珠单抗若与蒽环类化疗药物并用时，心脏毒性风险明显增加。紫杉醇类与CYP3A4酶相关药物（如部分抗癫痫药、抗真菌药）合用，会改变其代谢速率，提高毒性风险。\n    \u003C/p>\n    \u003Cdiv class=\"bcg-guide-tip bcg-guide-tip4\">\n      ⚠️ \u003Cspan>需要注意：\u003C/span> 治疗期间避免自行服用中草药、保健品以及葡萄柚、柚子等会影响药物代谢的食物。\n      \u003Cbr>\n      \u003Cstrong>正确做法：\u003C/strong> 如确需服用其他药物，请务必事先与医生说明全部正在使用的药物。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"bcg-guide-section bcg-guide-bg6\">\n    \u003Ch2 class=\"bcg-guide-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 👶 老年、特殊人群与剂量调整\u003C/h2>\n    \u003Cp class=\"bcg-guide-p\">\n      老年患者因代谢减慢、心肝肾功能减退，用药风险增加。肝肾功能异常、药物代谢障碍者需严格评估是否可以常规剂量使用曲妥珠单抗、紫杉醇等，部分患者可能需要降低剂量或者延长给药间隔。妊娠及哺乳期女性禁用大多数抗肿瘤药。\n    \u003C/p>\n    \u003Cdiv class=\"bcg-guide-tip bcg-guide-tip5\">\n      🔄 \u003Cspan>正确做法：\u003C/span> 接受治疗前，务必让医生知晓全部基础疾病史、用药史。如出现肝肾功能异常（如GGT升高），需严格个体化调整方案。\n    \u003C/div>\n    \u003Cp class=\"bcg-guide-sub\">\n      一名老年患者用化疗联合靶向药过程中，由于肝功能临时升高，及时调整用药间隔后，不良反应明显减少。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"bcg-guide-section bcg-guide-bg7\">\n    \u003Ch2 class=\"bcg-guide-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 😣 常见不良反应及处理办法\u003C/h2>\n    \u003Cp class=\"bcg-guide-p\">\n      使用靶向药、化疗药过程中，常见副作用有注射部位反应、过敏、乏力、白细胞减少、心脏毒性等。曲妥珠单抗心脏毒性发生率约2%-7%（Perez, E.A., et al. \"Cardiac Safety of Trastuzumab\", JCO, 2008），而紫杉醇类最常见为白细胞减少和神经病变。部分人群会出现皮疹或轻度发热。\n    \u003C/p>\n    \u003Cdiv class=\"bcg-guide-tip bcg-guide-tip6\">\n      🟠 \u003Cspan>正确做法：\u003C/span> 过程中若遇胸闷、呼吸急促、皮肤瘙痒、溃疡、发烧等均应及时报告医护人员。\n    \u003C/div>\n    \u003Cdiv class=\"bcg-guide-tip bcg-guide-tip7\">\n      \u003Cspan>特别提醒：\u003C/span> 对药物过敏者、曾出现心脏毒性人群禁止继续使用相关药品。\n    \u003C/div>\n    \u003Cp class=\"bcg-guide-sub\">\n      \u003Cspan>不良反应处理：\u003C/span> 出现白细胞减少时，可在医生指导下暂缓给药或调整方案；如有心脏不适，需行心脏功能检测。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"bcg-guide-section bcg-guide-bg1\">\n    \u003Ch2 class=\"bcg-guide-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 🗃️ 储存方法与有效期把控\u003C/h2>\n    \u003Cp class=\"bcg-guide-p\">\n      HER-2靶向药品与紫杉醇类药物，应冷藏于2-8℃避光密闭环境，禁止冷冻，不得暴露于高温或阳光直射。开瓶后药液需现配现用。过期、变色、浑浊药品严禁使用。\n    \u003C/p>\n    \u003Cdiv class=\"bcg-guide-tip bcg-guide-tip8\">\n      ✅ \u003Cspan>正确做法：\u003C/span> 家庭中无需自行储存此类药品。运输、保存、配置均须由专业药房和医疗机构专人操作。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"bcg-guide-section bcg-guide-bg2\">\n    \u003Ch2 class=\"bcg-guide-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 😕 漏服和过量处理\u003C/h2>\n    \u003Cp class=\"bcg-guide-p\">\n      靶向药和化疗药物漏服后不可随意自行补加剂量。如果错过一次给药，应尽快与主治医生取得联系，并听从专业安排调整下一次用药时间。随机补加容易增加毒副作用。过量用药可能出现严重毒性反应，需立即就医。\n    \u003C/p>\n    \u003Cdiv class=\"bcg-guide-tip bcg-guide-tip9\">\n      ⚠️ \u003Cspan>切记：\u003C/span> 千万不要自行补打，不随意更改给药时间，更不可擅自延长剂量间隔。\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"bcg-guide-section bcg-guide-bg3\">\n    \u003Ch2 class=\"bcg-guide-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 📝 小结 & 贴士\u003C/h2>\n    \u003Cp class=\"bcg-guide-p\">\n      HER-2靶向药（曲妥珠单抗、帕妥珠单抗）和紫杉醇类是乳腺肿瘤综合治疗的关键工具。正确的用药管理，包括按时定量给药、避免相互作用、关注不良反应、临床随访检查，是保障疗效与安全的基础。\n    \u003C/p>\n    \u003Cul class=\"bcg-guide-list\">\n      \u003Cli>用药前请主动告知医生全部用药史及特殊病史。\u003C/li>\n      \u003Cli>过程中出现不适必须及时报告医护人员，绝不自行调整用药。\u003C/li>\n      \u003Cli>所有药品应交由专业机构保存，全程由医护人员操作给药。\u003C/li>\n      \u003Cli>如漏服、过量或突发状况必须第一时间联系医生。\u003C/li>\n      \u003Cli>合理安排药物随访、监测心肝肾功能，是用药安全的基础。\u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"bcg-guide-p\">\n      这些细节看似琐碎，却是用药成功的关键。如果用药过程中有疑问，随时向医生或药师咨询，才能真正实现“安全用药、疗效有保障”。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"bcg-guide-refbox\">\n      \u003Ch3 class=\"bcg-guide-ref-h3\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献：References\u003C/h3>\n      \u003Col class=\"bcg-guide-ref-list\">\n        \u003Cli>Swain, S.M., Kim, S.B., Cortés, J., et al. (2015). Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Breast Cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 372(8), 724-734.\u003C/li>\n        \u003Cli>Perez, E.A., Rodeheffer, R., Tenner, L., et al. (2008). Cardiac Safety of Trastuzumab in the Treatment of Breast Cancer. \u003Ci>Journal of Clinical Oncology\u003C/i>, 26(8), 1231-1237.\u003C/li>\n        \u003Cli>Cortes, J., et al. (2012). Safety and Efficacy of Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer: Results from the CLEOPATRA Study. \u003Ci>Journal of Clinical Oncology\u003C/i>, 30(21), 2458-2465.\u003C/li>\n        \u003Cli>Marty, M., Cognetti, F., Maraninchi, D., et al. (2005). Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined with Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered as First-Line Treatment: The M77001 Study Group. \u003Ci>Journal of Clinical Oncology\u003C/i>, 23(19), 4265-4274.\u003C/li>\n        \u003Cli>Hortobagyi, G.N., et al. (2017). New Developments in the Management of HER2-Positive Breast Cancer: Focus on Pertuzumab. \u003Ci>Annals of Oncology\u003C/i>, 28(suppl_1), i1–i4.\u003C/li>\n      \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.bcg-guide-main {\n  max-width: 850px;\n  margin: 30px auto 60px auto;\n  background: #ffffff;\n  border-radius: 20px;\n  box-shadow: 0 6px 40px rgba(70, 110, 140, 0.10);\n  font-family: \"PingFang SC\",\"Microsoft YaHei\", Arial, sans-serif;\n  padding: 38px 42px 40px 42px;\n  box-sizing: border-box;\n  color: #19364d;\n}\n.bcg-guide-title {\n  font-size: 36px;\n  letter-spacing: 1px;\n  font-weight: bold;\n  text-align: center;\n  background: linear-gradient(to right, #fceabb, #f8b500 70%);\n  border-radius: 18px;\n  margin-bottom: 38px;\n  padding: 24px 18px 16px 18px;\n  color: #39301a;\n  box-shadow: 0 2px 8px rgba(240, 170, 50, 0.07);\n}\n.bcg-guide-section {\n  margin-bottom: 27px;\n  border-radius: 15px;\n  padding: 30px 30px 18px 32px;\n  box-sizing: border-box;\n  box-shadow: 0 0px 7px rgba(140,170,210,0.10);\n}\n.bcg-guide-bg1 {\n  background: linear-gradient(98deg, #faf6f2 60%, #f5f9ee 100%);\n}\n.bcg-guide-bg2 {\n  background: linear-gradient(120deg, #f3f0ff 70%, #e6f4ff 100%);\n}\n.bcg-guide-bg3 {\n  background: linear-gradient(120deg, #e0f7fa 0%, #f2f5ff 100%);\n}\n.bcg-guide-bg4 {\n  background: linear-gradient(98deg, #f0fff0 30%, #fffde9 100%);\n}\n.bcg-guide-bg5 {\n  background: linear-gradient(120deg, #f8f3df 44%, #e9f8ec 100%);\n}\n.bcg-guide-bg6 {\n  background: linear-gradient(99deg, #ecf2fe 0%, #e6f2ed 100%);\n}\n.bcg-guide-bg7 {\n  background: linear-gradient(120deg, #fffaf5 50%, #fbeded 100%);\n}\n.bcg-guide-h2 {\n  font-size: 28px;\n  font-weight: 600;\n  margin: 0 0 15px 0;\n  padding: 0;\n  letter-spacing: 0.5px;\n  line-height: 36px;\n  color: #215b8b;\n  text-shadow: 0 1px 0 #fff3d0;\n}\n.bcg-guide-p {\n  font-size: 18px;\n  line-height: 29px;\n  margin: 0 0 11px 0;\n  color: #244259;\n}\n.bcg-guide-tip {\n  background: #f7fbe7;\n  border-left: 6px solid #c3e988;\n  color: #224015;\n  padding: 9px 19px 8px 15px;\n  border-radius: 7px;\n  font-size: 16px;\n  margin: 15px 0 12px 0;\n  line-height: 23px;\n  box-sizing: border-box;\n}\n.bcg-guide-tip1 { border-color: #8fd4fe; background: #f1faff; }\n.bcg-guide-tip2 { border-color: #ffd18b; background: #fff6e9; }\n.bcg-guide-tip3 { border-color: #c1a8f5; background: #f9f7fd;}\n.bcg-guide-tip4 { border-color: #fad6a5; background: #fef6e8;}\n.bcg-guide-tip5 { border-color: #a8eac1; background: #f5fdec;}\n.bcg-guide-tip6 { border-color: #febeb3; background: #fff3f2;}\n.bcg-guide-tip7 { border-color: #ffa06a; background: #fff9f3;}\n.bcg-guide-tip8 { border-color: #99c0ff; background: #f2f7ff;}\n.bcg-guide-tip9 { border-color: #f57c7c; background: #fff0f0;}\n.bcg-guide-sub {\n  margin: 8px 0 6px 0;\n  font-size: 16px;\n  color: #31382c;\n  background: #f6f5f1;\n  border-left: 4px solid #f8eeb8;\n  padding: 8px 18px 7px 12px;\n  border-radius: 6px;\n}\n.bcg-guide-list {\n  margin: 10px 0 17px 21px;\n  color: #3b404c;\n  font-size: 17px;\n  line-height: 26px;\n}\n.bcg-guide-list li {\n  margin-bottom: 5px;\n  list-style-type: disc;\n}\n.bcg-guide-refbox {\n  background: #f8fafc;\n  padding: 36px 23px 27px 23px;\n  border-radius: 13px;\n  margin-top: 38px;\n  box-shadow: 0 1px 7px rgba(180,200,210,0.08);\n}\n.bcg-guide-ref-h3 {\n  font-size: 21px;\n  font-weight: 600;\n  color: #5371a3;\n  margin-bottom: 17px;\n  letter-spacing: 0.5px;\n}\n.bcg-guide-ref-list {\n  font-size: 16px;\n  color: #3e485a;\n  padding-left: 19px;\n  line-height: 24px;\n}\n.bcg-guide-ref-list li {\n  margin-bottom: 7px;\n}\n@media (max-width: 660px) {\n  .bcg-guide-main {\n    padding: 13px 6px 24px 6px;\n    border-radius: 6px;\n    box-shadow: 0 0 7px rgba(120,120,120,0.10);\n  }\n  .bcg-guide-title {\n    font-size: 22px;\n    padding: 14px 2px 8px 2px;\n    border-radius: 10px;\n  }\n  .bcg-guide-section {\n    padding: 16px 6px 14px 10px;\n    border-radius: 7px;\n  }\n  .bcg-guide-h2 {\n    font-size: 17px;\n    line-height: 23px;\n    margin-bottom: 6px;\n  }\n  .bcg-guide-p, .bcg-guide-sub {\n    font-size: 14px;\n    line-height: 21px;\n    padding: 0 2px;\n  }\n  .bcg-guide-tip {\n    font-size: 13px;\n    padding: 6px 8px 7px 8px;\n    border-radius: 4px;\n  }\n  .bcg-guide-refbox {\n    margin-top: 12px;\n    padding: 12px 4px 13px 8px;\n    border-radius: 5px;\n  }\n  .bcg-guide-ref-h3 {\n    font-size: 14px;\n    margin-bottom: 5px;\n  }\n  .bcg-guide-ref-list {\n    font-size: 12px;\n    padding-left: 9px;\n    line-height: 18px;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"bcg-guide-main\">\n  \u003Ch2 id=\"material_title\" class=\"bcg-guide-title\" style=\"color: rgb(44,",509,"2025-07-03 16:47:02","HER-2乳腺癌,靶向药物,化疗药物,曲妥珠单抗,帕妥珠单抗,用药安全,老年患者用药,药物相互作用","了解HER-2过表达型乳腺癌的用药管理要点，包括靶向药物与化疗药物的安全使用，帮助患者在治疗中保障健康与疗效。","2025-07-04 23:34:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]